IMVT news

Immunovant reported $797.8M in cash and non-GAAP losses, with key topline data for CLE and D2T RA expected in late 2026. Only 90% of data provided for the Non-GAAP net loss figure in exhibit991202686.htm.

Immunovant announced positive Week 16 results from its IMVT-1402 trial in difficult-to-treat rheumatoid arthritis, with response rates of 72.7% ACR20, 54.5% ACR50, and 35.8% ACR70. The company discontinued batoclimab development to focus on IMVT-1402, which has multiple clinical programs underway wi…